| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | bid1870 | gCSI | pan-cancer | AAC | 0.19 | 0.0005 |
| mRNA | MG-132 | GDSC1000 | pan-cancer | AAC | -0.15 | 0.002 |
| mRNA | Irinotecan | gCSI | pan-cancer | AAC | -0.16 | 0.003 |
| mRNA | Erlotinib | gCSI | pan-cancer | AAC | 0.16 | 0.005 |
| mRNA | Gemcitabine | gCSI | pan-cancer | AAC | -0.14 | 0.009 |
| mRNA | QL-XII-61 | GDSC1000 | pan-cancer | AAC | -0.12 | 0.01 |
| mRNA | Gefitinib | CTRPv2 | pan-cancer | AAC | 0.091 | 0.01 |
| mRNA | PD-0325901 | GDSC1000 | pan-cancer | AAC | -0.078 | 0.01 |
| mRNA | SNX-2112 | GDSC1000 | pan-cancer | AAC | -0.07 | 0.02 |
| mRNA | tanespimycin:bortezomib (250:1 mol/mol) | CTRPv2 | pan-cancer | AAC | -0.087 | 0.02 |